Comprehensive Hereditary Panels-Hereditary Prostate Cancer
Unique Identifier:
ML-N005
Name on Requisition:
Comprehensive Hereditary Panels-Hereditary Prostate Cancer
Product Line:
NH
Panel Group:
Hereditary Cancer Panels
Panel Name:
Comprehensive Hereditary Panels-Hereditary Prostate Cancer
Methodology
Molecular
NGS
Test Description and clinical significance
Genes
ATM, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, PALB2, PMS2, RAD51C, RAD51D, TP53
Disease:
Prostate Cancer
The Hereditary Prostate Cancer Panel detects germline variants in genes associated with hereditary prostate cancer predisposition, including BRCA1, BRCA2, ATM, CHEK2, HOXB13, and others. Identification of pathogenic variants offers risk assessment, prognostic insight, and treatment guidance, particularly for PARP inhibitor–based and precision oncology approaches.
Specimen Requirements
Preparation:
PB, saliva
Collection:
Specimen should contain least 0.5 mL of peripheral blood (lower volumes may be accepted if situation demands), but we prefer larger specimens in case of a low content of nucleated cells. For saliva, it is recommended to request 1.5-2.0 ml of saliva to be collected from each patient.
Stability:
4 to 7 days refrigerated fpr PB and upto 1 year for slaiva at room temperature
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative or anticoagulant. Specimen received after the stability date. Gross hemolysis. Frozen specimen. Insufficient specimen. Unlabeled. Left un-refrigerated for an extended period.
Storage & Transport
4 to 7 days refrigerated fpr PB and upto 1 year for slaiva at room temperature
CPT(s)
81432
New York Approved
Yes
TAT
14-21
Requisition Type
NH
Levels of Service
Full
DexS Code
Z03NX
Prefix
MI
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
